NCT00095225已完成2 期
A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 122
- 试验地点
- 96
- 主要终点
- To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.
研究概览
简要总结
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Histologically or cytologically proven Stage IIIb with pleural effusion, or Stage IV, recurrent non-squamous NSCLC that is recurrent and unresectable
- •Progression after one line of platinum-based chemotherapy (patients who have received prior docetaxel treatment are eligible to participate if there are no contraindications for pemetrexed treatment)
- •Progression after previous adjuvant chemotherapy, if therapy was completed >= 6 months prior to randomization and the patient has received one line of therapy for recurrent disease
- •(Optional) Availability of archival diagnostic tissue (paraffin tissue block or 2-10 unstained slides representative of the patient's primary cancer)
- •ECOG performance status of 0, 1, or 2
- •Life expectancy >= 3 months
- •Measurable disease in accordance with RECIST
- •Age >= 18 years
- •Use of an acceptable means of contraception (potentially fertile men and women) or documentation of infertility
排除标准
- •More than 30 days of prior treatment with an investigational or marketed agent that acts by EGFR inhibition (those with 30 or fewer days on an EGFR inhibitor without disease progression are eligible for enrollment)
- •Treatment with an investigational or marketed agent that acts by anti-angiogenic mechanisms
- •Previous treatment with more than one platinum-based chemotherapy
- •Chemotherapy or radiotherapy within 28 days prior to randomization
- •History of hemoptysis (> 1 teaspoon) or presence of a cavitary lesion
- •Clinical history of Grade > 2 hematemesis within 6 months or Grade 1 hematemesis within 28 days prior to randomization
- •History of serious systemic disease, including myocardial infarction within the last 6 months, uncontrolled hypertension (blood pressure > 150/100 mmHg on medication), unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or Grade II or greater peripheral vascular disease
- •History or clinical evidence of CNS or brain metastases or CNS bleeding
- •History or clinical evidence of hemorrhagic or thrombotic stroke within the 6 months prior to randomization
- •Centrally located lesions and lesions that abut major blood vessels
- •Ongoing treatment with full-dose warfarin (or its equivalent) or heparin (or its equivalent; e.g., Lovenox(R))
- •In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
- •Minor surgical procedure, fine needle aspirations, or core biopsy within 7 days prior to randomization
- •Anticipation of need for a major surgical procedure during the course of the study
- •Serious, non-healing wound, ulcer, or bone fracture
- •Inability to take oral medication or requirement for IV alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption
- •Any of the following abnormal hematologic values (within 1 week prior to randomization): ANC <= 1,500 cells/uL; platelet count <= 100,000 cells/uL; Hemoglobin <= 9.0 g/dL; International normalized ratio (INR) > 1.5 x upper limit of normal (ULN)
- •For patients who will receive docetaxel, any of the following abnormal liver function tests (within 1 week prior to randomization): Serum bilirubin greater than ULN; Albumin <= 2.5 g/dL; Serum ALT >= 1.5 x ULN; Serum AST >= 1.5 x ULN; Alkaline phosphatase >= 2.5 x ULN
- •Other baseline laboratory values: Serum creatinine > 2.0 x ULN; Uncontrolled hypercalcemia ( > 11.5 mg/dL); Urinary protein/creatinine ratio >= 1 (spot urine) or clinically significant impairment of renal function; Estimated creatinine clearance < 45 mL/min (for patients who will receive pemetrexed)
- •Any active systemic bacterial, fungal, or viral infection, including known hepatitis C and HIV
- •Pregnant or breast-feeding
- •Presence of another cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix or non-melanomatous skin cancer
- •Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form
结局指标
主要结局
To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.
次要结局
未报告次要终点
研究者
研究点 (96)
Loading locations...
相似试验
已完成
2 期
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)Non-Small Cell Lung CancerNCT00854308Genentech, Inc.137
Unknown
2 期
Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaAdvanced Mucosal MelanomaNCT03941795Peking University Cancer Hospital & Institute99
已完成
2 期
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyTriple Negative Breast NeoplasmsHRpos Breast NeoplasmsBRCA 1 /2 and / or HRDBreast CancerNCT02789332German Breast Group107
已完成
2 期
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMMultiple MyelomaNCT01526694Azienda Ospedaliera di Bolzano30
Unknown
2 期
Brostallicin Clinical Trial for Myxoid LiposarcomaMyxoid LiposarcomaNCT00633165Systems Medicine LLC24